Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy

被引：13
|
作者：
Zenke, Frank T. [1 ]
Zimmermann, Astrid [1 ]
Dahmen, Heike [1 ]
Elenbaas, Brian [2 ]
Pollard, John [3 ]
Reaper, Philip [3 ]
Bagrodia, S. [4 ]
Spilker, M. E. [4 ]
Amendt, C. [1 ]
Blaukat, Andree [1 ]
机构：
[1] Merck KGaA, Darmstadt, Germany
[2] EMD Serono, Billerica, MA USA
[3] Vedex Pharmaceut Ltd, Abingdon, Oxon, England
[4] Pfizer Inc, San Diego, CA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-369
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
369
引用
收藏
页数：2
相关论文
共 50 条
  • [1] M1774, a novel potent and selective ATR inhibitor, shows antitumor effects as monotherapy and in combination
    Zimmermann, Astrid
    Dahmen, Heike
    Grombacher, Thomas
    Pehl, Ulrich
    Blaukat, Andree
    Zenke, Frank T.
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [2] A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours
    Howard A. Burris
    Jordan Berlin
    Tobias Arkenau
    Gregory M. Cote
    Martijn P. Lolkema
    Jordi Ferrer-Playan
    Anup Kalapur
    Jayaprakasam Bolleddula
    Giuseppe Locatelli
    Thomas Goddemeier
    Ioannis Gounaris
    Johann de Bono
    [J]. British Journal of Cancer, 2024, 130 : 1131 - 1140
  • [3] A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours
    Burris, Howard A.
    Berlin, Jordan
    Arkenau, Tobias
    Cote, Gregory M.
    Lolkema, Martijn P.
    Ferrer-Playan, Jordi
    Kalapur, Anup
    Bolleddula, Jayaprakasam
    Locatelli, Giuseppe
    Goddemeier, Thomas
    Gounaris, Ioannis
    de Bono, Johann
    [J]. BRITISH JOURNAL OF CANCER, 2024, 130 (07) : 1131 - 1140
  • [4] Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents
    Jo, Ukhyun
    Senatorov, Ilya S.
    Zimmermann, Astrid
    Saha, Liton Kumar
    Murai, Yasuhisa
    Kim, Se Hyun
    Rajapakse, Vinodh N.
    Elloumi, Fathi
    Takahashi, Nobuyuki
    Schultz, Christopher W.
    Thomas, Anish
    Zenke, Frank T.
    Pommier, Yves
    [J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (08) : 1431 - 1441
  • [5] Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress and enhances the chemotherapeutic activity of widely used DNA damaging agents.
    Jo, Ukhyun
    Senatorov, Ilya
    Zimmermann, Astrid
    Saha, Liton Kumar
    Murai, Yasuhisa
    Kim, Se Hyun
    Rajapakse, Vinodh N.
    Elloumi, Fathi
    Takahashi, Nobuyuki
    Schultz, Christopher
    Thomas, Anish
    Zenke, Frank
    Pommier, Yves
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [6] ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
    Wilson, Zena
    Odedra, Rajesh
    Wallez, Yann
    Wijnhoven, Paul W. G.
    Hughes, Adina M.
    Gerrard, Joe
    Jones, Gemma N.
    Bargh-Dawson, Hannah
    Brown, Elaine
    Young, Lucy A.
    O'Connor, Mark J.
    Lau, Alan
    [J]. CANCER RESEARCH, 2022, 82 (06) : 1140 - 1152
  • [7] The novel ATR inhibitor M4344 and CHK1 inhibitor SRA737 overcome chemoresistance in SLFN11-negative cells in combination treatment with DNA-damaging agents
    Jo, Ukhyun
    Murai, Yasuhisa
    Murai, Junko
    Huang, Shar-yin N.
    Chakka, Sirisha
    Chen, Lu
    Cheng, Ken
    Pommier, Yves
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [8] Development and validation of a quantitative systems pharmacology model for prediction of preclinical efficacy of PARP inhibitors rucaparib and talazoparib combined with the ATR inhibitor gartisertib (M4344)
    Villette, Claire C.
    Brightman, Frances
    Dupuy, Nathalie
    Zimmermann, Astrid
    Lignet, Florianne
    Zenke, Frank T.
    Terranova, Nadia
    Bolleddula, Jayaprakasam
    El Bawab, Samer
    Chassagnole, Christophe
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [9] RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
    Roulston, Anne
    Zimmermann, Michal
    Papp, Robert
    Skeldon, Alexander
    Pellerin, Charles
    Dumas-Berube, Emilie
    Dumais, Valerie
    Dorich, Stephane
    Fader, Lee D.
    Fournier, Sara
    Li, Li
    Leclaire, Marie-Eve
    Yin, Shou Yun
    Chefson, Amandine
    Alam, Hunain
    Yang, William
    Fugere-Desjardins, Chloe
    Vignini-Hammond, Sabrina
    Skorey, Kathryn
    Mulani, Amina
    Rimkunas, Victoria
    Veloso, Artur
    Hamel, Martine
    Stocco, Rino
    Mamane, Yael
    Li, Zuomei
    Young, Jordan T. F.
    Zinda, Michael
    Black, W. Cameron
    [J]. MOLECULAR CANCER THERAPEUTICS, 2022, 21 (02) : 245 - 256
  • [10] CH4987655 (RO4987655), a selective orally bioavailable MEK inhibitor, shows highly potent and broad antitumor activity as a monotherapy and in combination with other antitumor agents
    Aida, Satoshi
    Yoshimura, Yasushi
    Ishii, Nobuya
    Sakamoto, Hiroshi
    Isshiki, Yoshiaki
    Ishikawa, Yuji
    Miwa, Masanori
    Shimma, Nobuo
    Okabe, Hisafumi
    Aoki, Yuko
    [J]. CANCER RESEARCH, 2009, 69
12345